Galmed Pharmaceuticals
GLMD
20 hedge funds and large institutions have $23.4M invested in Galmed Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
5% less funds holding
Funds holding: 21 → 20 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
34% less capital invested
Capital invested by funds: $35.4M → $23.4M (-$12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$2.4M |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$457K |
| 3 |
Squarepoint
New York
|
+$111K |
| 4 |
Morgan Stanley
New York
|
+$84.9K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$58.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.11M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$1.38M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.11M |
| 4 |
Renaissance Technologies
New York
|
-$196K |
| 5 |
VF
Virtu Financial
New York
|
-$71K |
GLMD Hedge Fund Activity: Q3 2020 in Review
20 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2020, worth a combined $23.4M — down 34% from $35.4M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GLMD and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was Ibex Investors, adding an estimated $2.4M. The largest seller was Vivo Capital, exiting entirely with an estimated $4.11M sold.
- 20 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2020, down from 21 in Q2 2020.
- Funds reported $23.4M of Galmed Pharmaceuticals stock for Q3 2020, down 34% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q3 2020 and 4 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q3 2020 was Ibex Investors, an estimated $2.4M added.
- The largest Galmed Pharmaceuticals seller in Q3 2020 was Vivo Capital, an estimated $4.11M sold.
Based on aggregated 13F filings for Q3 2020.